Navigation Links
Butrans® (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
Date:10/26/2011

s multi-center, randomized, double-blind, placebo-controlled, parallel-group study employed an enriched design which included a run-in phase of up to 27 days in which 1,024 opioid-naive patients with moderate-to-severe chronic low back pain who were suboptimally responsive to their non-opioid therapy received open-label treatment with Butrans.  

Opioid-naive patients were defined as patients who were receiving less than 5 mg of oxycodone or the equivalent in the 14 days prior to screening, and who did not have a history of daily opioid use of greater than or equal to 5 mg of oxycodone or the equivalent for three months prior to screening, and who, in the opinion of the investigator, were not opioid dependent at time of entry to the study, had not benefitted from or had not tolerated non-opioid therapy, and were deemed to be appropriate candidates for an around-the-clock opioid analgesic regimen.  

Of the 1,024 patients who entered the open-label, dose-titration period, 53% were able to titrate to a tolerable and effective dose of Butrans and were randomized into a 12-week, double-blind treatment period.  Twenty-three percent (23%) of patients discontinued due to an adverse event from the open-label titration period and 14% discontinued due to lack of a therapeutic effect.  Of the patients who were randomized, the mean (SE) Numerical Rating Scale pain scores were 7.2 (0.08) and 7.2 (0.07) at screening and 2.6 (0.08) and 2.6 (0.07) at pre-randomization (beginning of double-blind phase) for the Butrans and placebo groups, respectively.

A total of 541 patients were randomized to receive Butrans (10 or 20 mcg/hour, N=257) or placebo (N=284) in a double-blinded fashion, based on tolerability and analgesic response at the end of the open-label titration period.  During the first seven days of double-blind treatment patients were allowed up to two tablets per day of immediate-release oxycodone 5 mg as supplemental analgesia to m
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
2. Purdue Pharma L.P. to Present Data From Clinical Program for Butrans™ (buprenorphine) Transdermal System CIII at PAINWeek® 2010
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
5. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
6. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
9. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
10. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
11. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...  Luminex Corporation (NASDAQ: LMNX ) today ... 30, 2014. Financial and operating highlights include the following: ... million, a 2 percent increase over the second quarter ... $8.3 million, a 9 percent increase over the second ... 268 multiplexing analyzers, which included 148 LX systems, 96 ...
(Date:7/28/2014)... 2014 /PRNewswire-iReach/ -- June 28 th , 2014 – Oncolab, ... the AMAS cancer test, is making its AACC debut (booth ... test, which is a serum-based in vitro immunoassay, has been ... significant tool in the fight against cancer recurrence. ... estimated 17 million cancer survivors in the US alone, the ...
(Date:7/28/2014)...  Air Products (NYSE: APD ) understands ... vital to any healthcare facility. This understanding has driven ... the efficiency of its oxygen supply systems, but also ... systems for emergency oxygen supply and high ... the 51 st ASHE Annual Conference & ...
Breaking Medicine Technology:Luminex Corporation Reports Second Quarter 2014 results 2Luminex Corporation Reports Second Quarter 2014 results 3Luminex Corporation Reports Second Quarter 2014 results 4Luminex Corporation Reports Second Quarter 2014 results 5Luminex Corporation Reports Second Quarter 2014 results 6Luminex Corporation Reports Second Quarter 2014 results 7Luminex Corporation Reports Second Quarter 2014 results 8Luminex Corporation Reports Second Quarter 2014 results 9Luminex Corporation Reports Second Quarter 2014 results 10Luminex Corporation Reports Second Quarter 2014 results 11Luminex Corporation Reports Second Quarter 2014 results 12Luminex Corporation Reports Second Quarter 2014 results 13Luminex Corporation Reports Second Quarter 2014 results 14Luminex Corporation Reports Second Quarter 2014 results 15Luminex Corporation Reports Second Quarter 2014 results 16Luminex Corporation Reports Second Quarter 2014 results 17Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3
... BOSTON, Feb. 16, 2011 MedAptus®, the market ... New England Baptist Hospital (NEBH) has selected the ... inpatient medicine providers. The NEBH hospitalist team, comprised ... MedAptus, Inpatient Edition via the web as well ...
... Feb. 15, 2011 Warner Chilcott plc (Nasdaq: WCRX ... full year 2010 financial results prior to the market opening on ... a press release, the Company will host a conference call for ... (Eastern Time) to review the results. To participate in the call, ...
Cached Medicine Technology:Hospitalists at New England Baptist Hospital Choose MedAptus 2
(Date:7/28/2014)... Massachusetts (PRWEB) July 28, 2014 ... Summit Provider Exchange technology solution in ... integration efforts and support collaboration with their New ... bed acute-care medical center located in New Jersey, ... seasonal visitors with a variety of inpatient and ...
(Date:7/28/2014)... Maureen Salamon ... News) -- Infants and children who are at risk ... be vaccinated against the infection, according to updated recommendations ... And routine vaccinations for the potentially deadly ... American Academy of Pediatrics says. In its first ...
(Date:7/28/2014)... News) -- British researchers report that an alternative to ... In their experiments, the scientists found that clasping ... person to the other than what is known as ... might suffice as a cultural substitute for the firm ... the August issue of the American Journal of ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... heart rhythm irregularities are more likely to get a pacemaker ... fact, the study of more than 16,000 people found that ... to get a pacemaker than those without the memory-robbing condition. ... folks with dementia are so much more likely to be ...
(Date:7/28/2014)... 28, 2014 SIMpalm helped its ... App is available on iTunes for download . Experience ... Audio Chef allows you to listen and cook along with ... way: simply get out the ingredients and equipment, press play, ... or prepare ingredients ahead of time, just relax and cook ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4
... in post-menopausal women after they stopped taking combined hormone ... will be reported in the March 5 edition of ... Rowan T. Chlebowski, M.D., Ph.D., a Los Angeles Biomedical ... the study. , This latest study reinforces the original ...
... N.C., March 4 DARA BioSciences(TM),(Nasdaq: DARA ... Drutz, MD to the,Board of Directors. Dr. Drutz ... serve on the Company,s Compensation Committee as well ... effective February,26, 2008., Richard Franco, Sr., DARA,s ...
... ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), today announced it ... 2008, after the U.S. markets close. ISTA will,host a ... and provide a commercial and pipeline update at 5:00 ... live conference call, U.S. and Canadian participants may,dial 866-831-6270; ...
... Initiative points to continued need for mammograms , , TUESDAY, ... cancer lingers after a woman stops taking combination hormone replacement ... in the March 5 issue of the Journal of ... the landmark Women,s Health Initiative (WHI). That trial was halted ...
... 2,500 researchers and professionals in the area of biomolecular science ... Conference & Exhibition of the Society for Biomolecular Sciences (SBS) ... advances in biotechnology, challenges and automation solutions in the field. ... years meeting include: , New Methods ...
... March 4 Perrigo Company,(Nasdaq: PRGO ; ... 20 mg,Omeprazole delayed released tablets to its retail ... same dose as Prilosec OTC(R). Under terms,of an ... is,the exclusive marketer and distributor for the store ...
Cached Medicine News:Health News:LA BioMed researcher says 'unexpected' increase in cancer risk found 2Health News:DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board 2Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 2Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 3Health News:Specialists in drug discovery and development convene 2Health News:Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets 2Health News:Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets 3
The DSL-10-3000 ACTIVE Ferritin Enzyme-Linked Immunosorbent (ELISA) Kit provides materials for the quantitative measurement of ferritin in serum....
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... Bio-Rad isotopic anemia assays ... minimal ,pipetting steps for ... about the processes ,involved ... the benefit to your ...
Medicine Products: